Oxford BioMedica Plc-Product Pipeline Review-2015

Oxford BioMedica Plc-Product Pipeline Review-2015

  • Products Id :- GMDHC07285CDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Oxford BioMedica Plc-Product Pipeline Review-2015


Global Markets Direct's, 'Oxford BioMedica plc-Product Pipeline Review-2015', provides an overview of the Oxford BioMedica plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oxford BioMedica plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Oxford BioMedica plc including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Oxford BioMedica plc's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Oxford BioMedica plc's pipeline products

Reasons To Buy

Evaluate Oxford BioMedica plc's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Oxford BioMedica plc in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Oxford BioMedica plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Oxford BioMedica plc and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oxford BioMedica plc

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Oxford BioMedica plc and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Oxford BioMedica Plc Snapshot 5

Oxford BioMedica Plc Overview 5

Key Information 5

Key Facts 5

Oxford BioMedica Plc-Research and Development Overview 6

Key Therapeutic Areas 6

Oxford BioMedica Plc-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

Oxford BioMedica Plc-Pipeline Products Glance 12

Oxford BioMedica Plc-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Oxford BioMedica Plc-Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Oxford BioMedica Plc-Drug Profiles 16

TroVax 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

OXB-102 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

ProSavin 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

RetinoStat 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

EncorStat 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

EndoAngio-GT 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Glaucoma-GT 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MoNuDin 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibodies to Target 5T4 for Oncology 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Oxford BioMedica Plc-Pipeline Analysis 28

Oxford BioMedica Plc-Pipeline Products by Target 28

Oxford BioMedica Plc-Pipeline Products by Route of Administration 29

Oxford BioMedica Plc-Pipeline Products by Molecule Type 30

Oxford BioMedica Plc-Pipeline Products by Mechanism of Action 31

Oxford BioMedica Plc-Recent Pipeline Updates 32

Oxford BioMedica Plc-Dormant Projects 37

Oxford BioMedica Plc-Company Statement 38

Oxford BioMedica Plc-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

Oxford BioMedica Plc, Key Information 5

Oxford BioMedica Plc, Key Facts 5

Oxford BioMedica Plc-Pipeline by Indication, 2015 7

Oxford BioMedica Plc-Pipeline by Stage of Development, 2015 8

Oxford BioMedica Plc-Monotherapy Products in Pipeline, 2015 9

Oxford BioMedica Plc-Out-Licensed Products in Pipeline, 2015 10

Oxford BioMedica Plc-Out-Licensed Products/ Combination Treatment Modalities, 2015 11

Oxford BioMedica Plc-Phase II, 2015 12

Oxford BioMedica Plc-Phase I, 2015 13

Oxford BioMedica Plc-Preclinical, 2015 14

Oxford BioMedica Plc-Discovery, 2015 15

Oxford BioMedica Plc-Pipeline by Target, 2015 28

Oxford BioMedica Plc-Pipeline by Route of Administration, 2015 29

Oxford BioMedica Plc-Pipeline by Molecule Type, 2015 30

Oxford BioMedica Plc-Pipeline Products by Mechanism of Action, 2015 31

Oxford BioMedica Plc-Recent Pipeline Updates, 2015 32

Oxford BioMedica Plc-Dormant Developmental Projects,2015 37

Oxford BioMedica Plc, Subsidiaries 40

List of Figures

Oxford BioMedica Plc-Pipeline by Top 10 Indication, 2015 7

Oxford BioMedica Plc-Pipeline by Stage of Development, 2015 8

Oxford BioMedica Plc-Monotherapy Products in Pipeline, 2015 9

Oxford BioMedica Plc-Out-Licensed Products in Pipeline, 2015 10

Oxford BioMedica Plc-Pipeline by Top 10 Target, 2015 28

Oxford BioMedica Plc-Pipeline by Top 10 Route of Administration, 2015 29

Oxford BioMedica Plc-Pipeline by Top 10 Molecule Type, 2015 30

Oxford BioMedica Plc-Pipeline Products by Top 10 Mechanism of Action, 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Oxford BioMedica plc; Oxford BioMedica plc - Key Therapeutics; Oxford BioMedica plc - Pipeline Overview and Promising Molecules; Oxford BioMedica plc - News; Oxford BioMedica plc - Latest Updates; Oxford BioMedica plc - Pipeline; Oxford BioMedica plc - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97335
Site License
USD 3000 INR 194670
Corporate User License
USD 4500 INR 292005



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com